SYRE climbs on progress in long-acting autoimmune antibody programs
SYRE is highlighted for significant progress in long-acting antibody therapies for autoimmune diseases, including IBD and expansion into rheumatic and dermatologic indications, with combination strategies supported by resources for multiple late-stage trials.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.